Ono takes on Takeda in polycythemia vera
The Japanese group licenses sapablursen from Ionis for $280m.
The Japanese group licenses sapablursen from Ionis for $280m.
Rusfertide, the subject of a 2024 tie-up, scores in phase 3.
Rusfertide’s big readout will now not come until 2025.